Profound Medical Corp. (PROF) |
| 7.01 -0.24 (-3.31%) 10-13 16:00 |
| Open: | 7.19 |
| High: | 7.19 |
| Low: | 6.84 |
| Volume: | 371,317 |
| Market Cap: | 255(M) |
| PE Ratio: | -7.15 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 8.58 |
| Resistance 1: | 7.35 |
| Pivot price: | 6.14 |
| Support 1: | 6.21 |
| Support 2: | 5.50 |
| 52w High: | 8.95 |
| 52w Low: | 4.8 |
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
| EPS | -0.990 |
| Book Value | 1.360 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.375 |
| Profit Margin (%) | -171.56 |
| Operating Margin (%) | -445.67 |
| Return on Assets (ttm) | -39.5 |
| Return on Equity (ttm) | -73.5 |
Fri, 09 Oct 2026
Physician webinars are planned under Profound Medical (PROF) and Telix’s prostate care education pact. - Stock Titan
Fri, 09 Oct 2026
Profound Medical signs Telix prostate imaging agreement - grafa.com
Fri, 09 Oct 2026
Profound Medical: Q3 Revenue Beats Outlook (Rating Upgrade) - Seeking Alpha
Fri, 09 Oct 2026
Profound Medical, Telix enter co-education agreement - Investing.com
Fri, 09 Oct 2026
Profound Medical, Telix Pharmaceuticals Enter Prostate-Care Education Agreement - Yahoo Finance
Fri, 09 Oct 2026
The companies plan to teach doctors how prostate scans complement MRI-guided treatment. - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |